Chris LowePresident, CEO and Director
Chris has over 15 years of senior management experience as President, CBO and CFO of various private and public life sciences, medical technology, and technology companies. Additionally, he has served as a member of the Board of Directors of both public and private companies, and has chaired their respective Audit Committees and Compensation Committees.
During his career as a C-level executive, Chris has successfully raised over $500M in private and public financings, completed over $1.0B in M&A transactions, negotiated over $300M in debt instruments for companies. From 2007 – 2013 he served as the Chief financial Officer at Anthera Pharmaceuticals, a pharmaceutical development company, and from 2010 – 2013 also served as Chief Business Officer at Anthera Pharmaceuticals. Most recently beginning in 2014, Chris was interim CEO and subsequently CFO for Hansen Medical (HNSN) until the sale of the company to Auris Robotics in July 2016. Chris has also served as a partner in FLG Partners since January 2014.
Chris earned his B.S. from California Polytechnic State University – San Luis Obispo, and a MBA from St Mary’s University. Chris currently sits on the Board of Directors of Epibiome.
Ronald Shazer M.D.SVP & Chief Medical Officer
Dr. Ronald L. Shazer, M.D., M.B.A. joined Inspyr Therapeutics in August 2016 as Senior Vice President and Chief Medical Officer. Previously Dr. Shazer served as TRACON Pharmaceuticals Inc., Chief Medical Officer since October 2015. Dr. Shazer served as Senior Director, Clinical Lead Oncology at Pfizer where he led the clinical development of multiple oncology compounds including antibody drug conjugates, dual targeting T-cell engaging antibodies, and immuno-oncology small molecules. Prior to Pfizer, he served as a Director, Global Clinical Research Oncology at Bristol-Myers Squibb from 2011 to 2013 and served as the study lead on the registrational study for elotuzumab (Empliciti™), that subsequently received FDA approval. Prior to Bristol-Myers Squibb, he served as the Head of Clinical Development at Arena Pharmaceuticals during the filing of the NDA for lorcaserin (Belviq®). Dr. Shazer held academic positions in the Department of Medicine at the University of California, San Diego, University of California, Los Angeles School of Medicine, and Cedars-Sinai Medical Center. He completed his residency in internal medicine at Cedars-Sinai Medical Center in 2004. Dr. Shazer earned his B.A. in Economics from the University of California, San Diego, M.D. from the New York Medical College and M.B.A from the Anderson School of Management, University of California, Los Angeles.
Russell Richerson, PhDCOO
Russell B. Richerson, PhD, joined Inspyr in September 2009. He has over 25 years of experience in the Biotechnology/Diagnostics industry, including 11 years at Abbott Laboratories in numerous management roles. He also has extensive experience in senior research and development positions at companies such as Boehringer Mannheim, Du Pont, Prometheus Laboratories, Ventana Medical Systems, and the Molecular Profiling Institute. Dr. Richerson recently served on the board of the International Genomics Consortium (IGC), a non-profit medical research organization located in Phoenix, Arizona. Dr. Richerson received his PhD from the University of Texas at Austin in 1983
Michael ElliottVice President of Clinical Operations
Michael Elliott has two decades of experience in clinical trial management, spanning Phase 1 through pivotal Phase 3 trials, both in the United States and internationally in over 20 countries. Over the course of his career, Mr. Elliott has managed 59 company-sponsored clinical trials and 9 investigator-sponsored trials. Before joining Inspyr, Michael was Senior Director, Clinical Operations at NGM Biopharmaceuticals. In this role, he led the clinical operations group for this company, which has multiple programs studying first-in-class, first-in-human product candidates. Previously, he was Director, Clinical Development at Afferent Pharmaceuticals, a company which was acquired by Merck. Prior to Afferent, he was Director, Clinical Operations at Anthera Pharmaceuticals where he led multiple clinical studies and supported the regulatory submission for a Special Protocol Assessment (SPA) with the U.S. Food and Drug Administration (FDA). Earlier in his career, Michael managed clinical research at Stanford University and the University of California San Francisco. Michael earned a Bachelor of Arts from the University of Pittsburgh and a Master of Arts from Xavier University.